Trial Search Results
Hypofractionated Radiotherapy for Localized Prostate Cancer (With CyberKnife or With IMRT)
To demonstrate that a hypo-fractionated course of radiotherapy (ie. an accelerated radiotherapy course where fewer but larger doses of radiotherapy are given) is both safe and effective in the treatment of low-risk localized prostate cancer.
Stanford is currently not accepting patients for this trial.
- Procedure: Hypo-fractionated Radiotherapy
Inclusion Criteria:- Eligible patients will have clinical stage T1c through T2b, initial
PSA level <10 and a biopsy Gleason score of 3+3 or 3+4 with fewer than 50% of biopsy cores
- Patients who have had any form of prior curative treatment (surgery, radiotherapy,
cryotherapy) will not be eligible. A prior course of hormone therapy of less than 3
months duration will be allowed.
- Adult men will be considered.
- No life expectancy restrictions will apply.
- Performance Status will not be considered.
- No requirements for organ or marrow function will be made
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:- No prior prostate treatment will be allowed.
- The use of other concurrent Investigational Agents will not be allowed.
- No exclusion requirements due to co-morbid disease or incurrent illness.
- No requirements regarding history of allergic reactions.
- Pregnancy or nursing patients is not applicable (ie. patients are male).
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study